Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 2
2009 1
2011 1
2012 5
2013 6
2014 3
2015 4
2016 2
2017 4
2018 9
2019 3
2020 3
2021 6
2022 3
2023 5
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Results by year

Filters applied: . Clear all
Page 1
A 3-Year Course Of Bulevirtide Monotherapy May Cure Hdv Infection In Cirrhotics.
Anolli MP, Degasperi E, Allweiss L, Sangiovanni A, Maggioni M, Scholtes C, Oberhardt V, Neumann-Haefelin C, Dandri M, Zoulim F, Lampertico P. Anolli MP, et al. Among authors: scholtes c. J Hepatol. 2023 Jan 3:S0168-8278(22)03475-4. doi: 10.1016/j.jhep.2022.12.023. Online ahead of print. J Hepatol. 2023. PMID: 36931396
Early intrahepatic recurrence of HBV infection in liver transplant recipients despite antiviral prophylaxis.
Villeret F, Lebossé F, Radenne S, Samuel D, Roche B, Mabrut JY, Leroy V, Pageaux GP, Anty R, Thevenon S, Ahmed SS, Hamilton A, Heil M, Scholtès C, Levrero M, Testoni B, Zoulim F; ECOGREFFE Study Group. Villeret F, et al. Among authors: scholtes c. JHEP Rep. 2023 Mar 10;5(6):100728. doi: 10.1016/j.jhepr.2023.100728. eCollection 2023 Jun. JHEP Rep. 2023. PMID: 37122357 Free PMC article.
Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension.
Degasperi E, Anolli MP, Uceda Renteria SC, Sambarino D, Borghi M, Perbellini R, Scholtes C, Facchetti F, Loglio A, Monico S, Fraquelli M, Costantino A, Ceriotti F, Zoulim F, Lampertico P. Degasperi E, et al. Among authors: scholtes c. J Hepatol. 2022 Dec;77(6):1525-1531. doi: 10.1016/j.jhep.2022.07.016. Epub 2022 Aug 13. J Hepatol. 2022. PMID: 35973578
Viruses traverse the human proteome through peptide interfaces that can be biomimetically leveraged for drug discovery.
Meyniel-Schicklin L, Amaudrut J, Mallinjoud P, Guillier F, Mangeot PE, Lines L, Aublin-Gex A, Scholtes C, Punginelli C, Joly S, Vasseur F, Manet E, Gruffat H, Henry T, Halitim F, Paparin JL, Machin P, Darteil R, Sampson D, Mikaelian I, Lane L, Navratil V, Golinelli-Cohen MP, Terzi F, André P, Lotteau V, Vonderscher J, Meldrum EC, de Chassey B. Meyniel-Schicklin L, et al. Among authors: scholtes c. Proc Natl Acad Sci U S A. 2024 Jan 30;121(5):e2308776121. doi: 10.1073/pnas.2308776121. Epub 2024 Jan 22. Proc Natl Acad Sci U S A. 2024. PMID: 38252831 Free PMC article.
Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis.
Loglio A, Ferenci P, Uceda Renteria SC, Tham CYL, Scholtes C, Holzmann H, van Bömmel F, Borghi M, Perbellini R, Rimondi A, Farina E, Trombetta E, Manunta M, Porretti L, Prati D, Ceriotti F, Zoulim F, Bertoletti A, Lampertico P. Loglio A, et al. Among authors: scholtes c. J Hepatol. 2022 Feb;76(2):464-469. doi: 10.1016/j.jhep.2021.10.012. Epub 2021 Oct 23. J Hepatol. 2022. PMID: 34699951
55 results